SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C224 - Controversies in Multiple Sclerosis Therapy

Event Time: Friday April 28, 2017 7:00 am to 9:00 am
Topic(s): MS and CNS Inflammatory Disease
Director(s): Riley Bove MD
Description: Disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) are considered to be most effective when started early in the course of the disease. Should patients with clinically and radiologically isolated syndromes be started on disease modifying therapy? Should MS patients with stable disease be trialed off of MS disease-modifying therapy and if so, under what circumstances? Should all MS patients with seropositivity for JC virus antibody discontinue natalizumab treatment? Should all patients with MS be treated with vitamin D supplementation? Definitive evidence-based criteria may remain uncertain, but faculty will discuss and debate the merits, the available evidence, and their own clinical experience that can assist participants in making these important treatment decisions.
Completion Message: Participants should be able to describe and discuss the relative pros and cons of a number of controversies in MS evaluation and therapy.
CME Credits: 2
Core Competencies: Interpersonal and Communication Skills, Medical Knowledge, Patient Care, Practice-Based Learning and Improvement

Program Speakers - Tentative

Start/End Time Title Faculty
7:00 AM - 7:20 AM All Patients with CIS and RIS Should Start MS Therapy Riley Bove MD 
7:20 AM - 7:30 AM Questions and Answers Faculty 
7:30 AM - 7:50 AM All JCV Positive MS Patients Should Discontinue Natalizumab Therapy Bruce Cree MD, PhD, MCR 
7:50 AM - 8:00 AM Questions and Answers Faculty 
8:00 AM - 8:20 AM All Patients with MS Should Be Treated with Vitamin D Supplementation Ellen Mowry MD, FAAN 
8:20 AM - 8:30 AM Questions and Answers Faculty 
8:30 AM - 8:50 AM Once Started, MS Therapies Should Be Continued for Life Ellen Mowry MD, FAAN 
8:50 AM - 9:00 AM Questions and Answers Faculty 


Speaker Disclosure
Riley Bove, MD Dr. Bove has nothing to disclose.

Bruce A. C. Cree, MD, PhD, MCR Bruce Cree has received consulting honoraria from AbbVie, Biogen, EMD Serono, Novartis and Shire..

Ellen M. Mowry, MD, FAAN Dr. Mowry has received personal compensation in an editorial capacity for UpToDate (royalties). Dr. Mowry has received research support from Biogen, Genzyme, Teva, SunPharma..

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN


Forgot Password?